IBRX News

IBRX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

DEADLINE ALERT for SMCI, IBRX, and PINS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights

IBRX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ImmunityBio, Inc. Securities Lawsuit — The Gross Law Firm

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

Pomerantz LLP Advises Shareholders of Class Action Involving ImmunityBio, Inc. – IBRX

IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ImmunityBio, Inc. (IBRX) Facing Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman